Commentary on Twitter (thread – click for more)
1/ How can we better manage dyspnea in people with advanced cancer?
Wonderful to see this new @ASCO Guideline out.
— Arjun Gupta (@guptaarjun90) February 23, 2021
Therapy for Stage IV Non–Small-Cell Lung Cancer With Driver Alterations: ASCO and OH (CCO) Joint Guideline Update19 Feb, 2021 | 02:04h | UTC
RCT: Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%18 Feb, 2021 | 02:34h | UTC
Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial – The Lancet
Commentary on Twitter
Phase 3 trial suggests #cemiplimab could be used as new first-line monotherapy option for patients with advanced non-small-cell #lungcancer with PD-L1 of at least 50%—it improved overall & progression-free survival compared with chemotherapy. Read https://t.co/O06Of6wx07 pic.twitter.com/KtQ24lEoR5
— The Lancet (@TheLancet) February 17, 2021